Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adeyinka Agbetoyin

Cardiovascular Disease Jackson, TN Medical Doctor

NPI 1922047422 CMS profile 359902

2968 North Highland Ave, Jackson, TN 38305

Open in the dashboard

General payments

$111,697

569 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adeyinka Agbetoyin of Jackson, TN is reported in the CMS Open Payments database as having received $111,697 across 569 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,190 58
2024 General $36,219 89
2023 General $33,607 71
2022 General $2,888 82
2021 General $1,432 86
2020 General $1,227 80
2019 General $3,136 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adeyinka Agbetoyin
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Adeyinka Agbetoyin were reported at $33,190. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Adeyinka Agbetoyin Cardiovascular Disease median Middle half National median
2019 $3,136 $450 $127–$1,392 $163
2020 $1,227 $242 $77–$751 $114
2021 $1,432 $335 $101–$1,037 $132
2022 $2,888 $395 $121–$1,211 $149
2023 $33,607 $443 $136–$1,283 $160
2024 $36,219 $450 $136–$1,323 $164
2025 $33,190 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $100,368 10 payments
  2. Penumbra, Inc. $1,393 2 payments
  3. Novartis Pharmaceuticals Corporation $1,196 109 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,154 50 payments
  5. Janssen Pharmaceuticals, Inc $980 64 payments
  6. Abbott Laboratories $855 8 payments
  7. Amarin Pharma Inc. $807 52 payments
  8. Amgen Inc. $804 43 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $543 33 payments
  10. Merck Sharp & Dohme Corporation $330 24 payments
  11. Other $3,266 174 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $100,200 7 payments
  2. Food and Beverage $10,328 557 payments
  3. Travel and Lodging $1,157 3 payments
  4. Education $12 2 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac Et $61,333 3 payments
  2. Auryon Laser System 100-120 Vac Cv $27,667 1 payment
  3. VenaCure 1470 Pro Et $6,400 2 payments
  4. VenaCure 1470 Pro Id $4,800 1 payment
  5. Indigo $1,393 2 payments
  6. LifeVest $1,154 50 payments
  7. XARELTO $980 64 payments
  8. Repatha $789 42 payments
  9. Perclose ProStyle $659 2 payments
  10. Vascepa $628 40 payments
  11. Other $6,296 398 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

3,663

Median for Cardiology: 2,533

Drug cost

$785,653

Median for Cardiology: $485,213

Branded share of claims

36.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 277 $212,267
Eliquis Apixaban Brand 160 $158,225
Entresto Sacubitril/Valsartan Brand 92 $97,830
Repatha Sureclick Evolocumab Brand 110 $92,927
Wegovy Semaglutide Brand 33 $45,171
Jardiance Empagliflozin Brand 41 $38,356
Brilinta Ticagrelor Brand 45 $30,127
Vascepa Icosapent Ethyl Brand 43 $22,375
Repatha Syringe Evolocumab Brand 19 $14,456
Farxiga Dapagliflozin Propanediol Brand 18 $13,370

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$694,444

Of which drugs: $18,350

Medicare patients

440

Average age 74

Services billed

7,803

234 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 51%
Diabetes 45%
Heart failure 40%
Chronic kidney disease 33%
Atrial fibrillation 30%
COPD 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 101 390 $1,949
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 20 1,793 $188

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $164
$164 92 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $97
$97 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $86
$86 160 —
Repatha
  • Amgen Inc. $86
$86 129 —
Wegovy
  • Novo Nordisk Inc $73
$73 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

569 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record